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Background: Mycobacterium bovis Bacille Calmette-Guérin (BCG) vaccine is widely administered to prevent
tuberculosis. Vaccine complications are rare. However, when BCG-related adverse reactions arise there is a need to
rapidly and reliably identify BCG from other members of the Mycobacterium tuberculosis complex (TBC). PCR assays
based on the detection of the regions of difference (RD), in particular RD1 and RD9, have been invaluable in the
identification of BCG. Prior to this study, specimens were identified through HPLC analysis at a local reference
laboratory taking up to 2 weeks for a result. We sought to expedite the identification process by validating a RD1,
RD9 and hsp65 PCR assay for the identification and differentiation of BCG from TBC.
Findings: In last past 3 years, we validated the RD1, RD9 and hsp65 PCR assay for 16 mycobacterial isolates obtained
from children who had experienced adverse reactions to BCG vaccination. In these cases, the clinician required a
definitive identification of the isolate. The RD1 and RD9 PCR profiles indicated that all 16 isolates were BCG whilst
amplification of the hsp65 target functioned as a PCR positive control. When tested against clinical M. tuberculosis
(MTB), reference and non-tuberculous mycobacteria the PCR assay demonstrated 100% sensitivity and specificity.
Conclusions: The RD1, RD9 and hsp65 PCR assay is a useful tool for the rapid and reliable identification of BCG. Its ease
of use has allowed it to be implemented in our clinical microbiology laboratory.
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Mycobacterium bovis Bacille Calmette-Guérin (BCG)
vaccine has been used extensively for almost the last
100 years for the prevention of TB. In countries with a
national childhood immunization programme, vaccin-
ation rates typically exceed >80% in neonates and infants
[1]. In Singapore, BCG vaccination is given to all new-
borns since 1957 and has contributed to an effective TB
Control Programme.
The BCG vaccine is regarded as safe. There is a very
low incidence of complications, ranging from 0.1 to 5
per 1000 vaccinated [2,3]. BCG-induced adverse events
can be broadly classified into local or disseminated disease
ranging from sub-cutaneous abscess and keloids, lymph-
adenopathy, suppurative lymphadenitis to systemic events* Correspondence: Jeanette_Teo@nuhs.edu.sg
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reproduction in any medium, provided the orsuch as osteitis and disseminated BCG disease [3,4]. The
risk of disseminated BCG disease escalates in HIV-infected
children [5]. Chemotherapy with anti-tuberculosis drugs
may be initiated to prevent further progression to dissemi-
nated disease however treatment is complicated by the
inherent resistance of all M. bovis strains to pyrazina-
mide [5,6]. Therefore, it is imperative to accurately iden-
tify and differentiate M. bovis BCG particularly from M.
tuberculosis.
The diagnostics of BCG is not straightforward. M.
bovis BCG belongs to the Mycobacterium tuberculosis
complex (TBC) of highly related organisms comprising
M. tuberculosis, M. africanum, M. bovis, M. microti and
M. canetii. The lack of clear-cut differentiation between
the members [7] impedes the identification of BCG.
Limited methods avail for the differentiation of members
of the TBC. Phenotypic biochemical assays can be highly
subjective making it unreliable for identification [8]. High
performance liquid chromatography (HPLC) analysis can. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Teo et al. BMC Research Notes 2013, 6:434 Page 2 of 6
http://www.biomedcentral.com/1756-0500/6/434separate BCG vaccine strains from M. tuberculosis and M.
bovis [9]. However, this approach is not pragmatic for the
routine diagnostic laboratory due to requirement of spe-
cialized equipment and protracted turnaround times.
Comparative genomics has revealed 16 regions of differ-
ence (RD) in M. bovis and M. bovis BCG strains, which
are absent in M. tuberculosis H37Rv. Regions RD1, RD9,
RD10 have been extensively studied. Their exclusive ab-
sence in all BCG vaccine strains and presence in TB
strains makes these loci reliable and accurate diagnostic
markers [10,11]. Deletion profiles based on these RD re-
gions have been employed successfully for the differenti-
ation of BCG and TB via PCR based approaches [12-14].
This study was initiated three years ago, in 2010, when
we sought to evaluate a PCR approach for the rapid
identification of BCG that would be suitable for imple-
mentation in our routine diagnostic microbiology labora-
tory. Prior to this, specimens were identified through
HPLC analysis at a local reference laboratory. Here, we
describe the clinical performance of the PCR assay based
on the detection of RD1 and RD9 regions for the identifi-
cation and differentiation of BCG from MTB.
Bacterial isolates used in the study comprised reference
strains and clinical isolates (Table 1). Reference mycobacter-
ial isolates were from the American Type Culture Collec-
tion (ATCC, Manassas, VA, USA) and non-mycobacterial
quality control strains Rhodococcus equi and Norcardia far-
cinica were from our laboratory. Clinical mycobacterial
specimens were obtained from (i) patients deemed to have
adverse reactions to BCG immunization hence requiring
definitive identification of the mycobacterial isolate (n=16),
(ii) patients with confirmed TB (n=32). The diagnosis of
tuberculosis was based on clinical and microbiological
findings whereby the cultures were positive for M. tubercu-
losis by the Xpert MTB/RIF real-time PCR assay (Cepheid,
Sunnyvale, CA) [15]. The isolation of clinical mycobacterial
isolates from patient specimens is described below. Ethical
approval was not required as the study was conducted for
the improvement of a public health service and in a man-
ner that subjects could not be identified.
Respiratory and non-respiratory specimens (including
pus and aspirate samples) were decontaminated according
to standard methods using N-acetyl-L-cysteine–sodium
hydroxide (NALC-NaOH) [16]. Tissue specimens were
thoroughly minced using a pair of sterile scissors before
the NALC-NaOH processing. Sediment from the speci-
men obtained by centrifugation at 3600 rpm for 15 min
was resuspended in phosphate-buffered saline pH 6.8 to a
final volume of 1.5 ml. Half of the sediment was used for
inoculation into the automated Mycobacteria Growth
Indicator Tube [MGIT, (Becton Dickinson,Cockeysville,
MD)] culture system and the other half was inoculated
into a Lowenstein-Jensen (LJ) slant. Cultures were incu-
bated at 37°C for 6 weeks in MGIT and 8 weeks on LJslants at 37°C and 5% CO2. Prior to transporting the pure
mycobacterial cultures out of the Biosafety Level 3 La-
boratory, the bacteria were killed by resuspending colonies
in 500 μl of sterile water and boiled in screw cap tubes for
10 min.
The detection of two regions of difference (RD1 and
RD9) was the basis of the PCR assay used to identify
and differentiate BCG from TBC [13] (Table 2). The
DNA template used for the PCR was 2 μl of boiled cul-
ture supernatant (above). For each isolate tested, three
sets of PCR reactions were setup enabling the detection
of RD1, RD9 and hsp65 (Table 2). The amplification of a
401 bp fragment from hsp65 served as a PCR positive
control for members of the MTB complex. PCR amplifica-
tion reactions were performed using HotStarTaq master
mix kit (Qiagen, Hilden, Germany) with an initial denatur-
ation at 95°C for 5 min, followed by 35 temperature cycles
of heat denaturation at 94°C for 30 s, primer annealing at
62°C for 90 s and extension at 72°C for 60 s and a final
step of extension at 72°C for 10 min. PCR products were
separated by electrophoresis in 1.5% agarose gel, stained
with ethidium bromide and visualized by UV transillumin-
ation. The results were positive when the specific size
product was observed (Table 2).
Additional tests used for the identification of members
of TBC include (i) AccuProbe Mycobacterium Tubercu-
losis Complex Culture Identification Test (Gen-Probe
Incorporated, San Diego, CA) is a rapid DNA probe test
utilizing nucleic acid hybridization for the identification
of TBC isolated from culture. Testing was performed in
accordance with the manufacturer's instructions. Briefly,
after bacterial lysis, a 100 μl sample was transferred to
the corresponding AccuProbe tube. Hybridization re-
sults, expressed as relative light units (RLUs), were de-
termined with a Leader 50 luminometer (GenProbe). A
positive reaction was a result > 30000 RLU. (ii) SD TB Ag
MPT64 Rapid (Standard Diagnostics, Seoul, South Korea)
is an immunochromatographic test using anti-MPT64
antibodies for the detection of the MPT64 antigen of
MTB isolates. The assay is used primarily to distinguish
between M. tuberculosis complex and non-tuberculous
mycobacteria (NTM). The kit was used according to the
manufacturer's protocol. Briefly, 100 μl of condensation
fluid from colonies growing in LJ slants were applied dir-
ectly to the sample well. Tests were interpreted 15 min
after sample application. The presence of only a control
band alone indicated a negative result whereas the appear-
ance of a second band (test band) indicated a positive re-
sult for MTB. (iii) oxyR sequencing. A single nucleotide
polymorphism in position 285 of the oxyR sequence al-
lows differentiation of M. bovis from the other members
of the TBC. All M. bovis strains have an adenine (A) resi-
due at nucleotide 285, whereas all M. tuberculosis strains
have guanine (G) residue at this position [14,17]. A 548 bp
Table 1 Characteristics of specimens sent for BCG identification, clinical MTB isolates and reference strains
Samples Disease description
and management





For BCG identification (n =16)
Case/Sex/Age (months)
1/M/3 BCG adentitis. Excision of
inguinal lymph node
Inguinal lymph node ― ― + M. bovis NEG ND
2/M/2 Incision and drainage of abscess Axillary abscess ― ― + M. bovis NEG POS
3/M/2 No information available Axillary abscess ― ― + M. bovis NEG POS
4/F/4 Incision and drainage of
gluteal abscess
Injection site abscess ― ― + M. bovis NEG POS
5/M/3 BCG adentitis. Excision of
inguinal lymph node
Inguinal lymph node ― ― + M. bovis NEG POS
6/F/3 No information available Inguinal lymph node ― ― + M. bovis NEG POS
7/M/3 No information available Inguinal lymph node ― ― + M. bovis NEG POS
8/F/3 No information available Inguinal lymph node ― ― + M. bovis NEG POS
9/M/4 BCG adenitis. Excision of
inguinal lymph node
Injection site abscess ― ― + M. bovis NEG POS
10/M/22 No information available Lymph node ― ― + M. bovis NEG POS
11/M/2 No information available Lymph node ― ― + M. bovis NEG POS
12/F/3 Left caseating inguinal lymph node. Lymph node ― ― + M. bovis NEG POS
13/M/3 No information available Inguinal lymph node ― ― + M. bovis NEG POS
14/M/4 Left axillary lymph node
abscess. Incision and drainage
Axillary abscess ― ― + M. bovis NEG POS
15/M/3 No information available Lymph node abscess ― ― + M. bovis NEG POS
16/M/3 No information available Inguinal lymph node aspirate ― ― + M. bovis NEG POS
For specificity and sensitivity testing
Clinical MTB isolates (n= 32) Respiratory and non-respiratory + + + ND POS POS
M. tuberculosis complex control strains (n=3)
M. bovis BCG Pasteur ATCC 35734 NA ― ― + M. bovis NEG POS
M. tuberculosis H37Ra ATCC 25177 NA + + + MTB POS POS
M. tuberculosis H37Rv ATCC 27294 NA + + + MTB POS POS
Non M. tuberculosis strains (n=13)
M. intracellulare ATCC 13950 NA ― ― ― ND ND- ND
M. gordonae ATCC 35756 NA ― ― ― ND ND ND



















Table 1 Characteristics of specimens sent for BCG identification, clinical MTB isolates and reference strains (Continued)
M. septicum ATCC 700731 NA ― ― ― ND ND ND
M. senegalense ATCC 35755 NA ― ― ― ND ND ND
M. perigrinum ATCC 23001 NA ― ― ― ND ND ND
M. xenopi ATCC 19250 NA ― ― ― ND ND ND
M. abscessus ATCC 19977 NA ― ― ― ND ND ND
M. chelonae ATCC 19539 NA ― ― ― ND ND ND
M. fortuitum ATCC 6841 NA ― ― ― ND ND ND
M. haemophilum ATCC 29548 NA ― ― ― ND ND ND
Rhodococcus equi NA ― ― ― ND ND ND
Norcardia farcinica NA ― ― ― ND ND ND
ND: Not done.
NA: Not applicable.
— : No PCR amplification observed.
+ : Positive PCR amplification.



















Table 2 PCR primers used in this study
Primer pair Sequence 5’- 3’ Target locus Amplicon size (bp) Reference
RD1 For CCGTTGGCAGCATTGGCGGCG RD1 126 This study
RD1 Rev CCGGGCCCAGGAATATAGCCAG
RD9 FF GTGTAGGTCAGCCCCATCC RD9 333 [13]
RD9 Int CAATGTTTGTTGCGCTGC
mycHsp65 left CCGAGCTGGTCAAAGAGGTA hsp65 401 This study
mycHsp65 right CACGAAGTACCCCGAGATGT
oxyR For GGTGATATATCACACCATA oxyR 548 [17]
oxyR Rev CTATGCGATCAGGCGTACTTG
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in Table 2. The PCR conditions used were based on a pub-
lished PCR protocol [17]. The amplicon was purified using
QIAquick PCR Purification Kit (Qiagen, Hilden, Germany)
and sequenced using the same set of primers.
The administration of the BCG vaccine rarely causes
complications. Mild injection site reactions are almost
universal upon vaccination, often taking the form of a
papule or scarring. Typically no treatment is required. Se-
vere local and systemic BCG-induced disease is a much
less frequent occurrence and may necessitate the initiation
of treatment with anti-tuberculosis drugs [3,4]. Hence, it
is critical to have rapid and accurate tests that can detect
M. bovis BCG and differentiate it from MTC so that the
clinician can choose the appropriate treatment.
Over the last 3 years, there were 16 cases submitted to
our laboratory requesting the differentiation of BCG from
MTB. BCG induced disease was suspected as adverse re-
actions arose shortly after vaccination and in close prox-
imity to the injection site. Clinical descriptions of the
cases where available are indicated on Table 1. In all cases
with surgical intervention, the patients healed well.
Molecular assays based on the RD deletion profiles
have been invaluable in differentiating members of the
TBC [12-14]. The complete absence of both RD1 and
RD9 is indicative of M. bovis BCG, conversely the pres-
ence of both RD1 and RD9 indicates M. tuberculosis.
Non-BCG M. bovis is distinguished from BCG by the
presence of RD1 and the absence of RD9 [12-14]. In this
study, none of the 16 isolates submitted for testing were
positive for RD1 or RD9, indicating they were M. bovis
BCG. These PCR results confirmed suspicions of BCG-
related disease in the recently vaccinated children (Table 1).
The RD1 and RD9 PCR assay was also evaluated using
clinical TB isolates (n=32), ATCC isolates of MTB and M.
bovis BCG Pasteur as well as NTMs and was determined
to have 100% specificity and sensitivity (Table 1). The PCR
assay includes a positive amplification control designed
specifically to detect the hsp65 gene from TBC members.
Performance of the hsp65 PCR control was also excellent,
exhibiting 100% specificity and sensitivity (Table 1).oxyR sequencing of the 16 isolates from suspected
BCG cases displayed the distinctive single nucleotide
polymorphism of M. bovis isolates with G➔A at position
285 [17] (Table 1). The oxyR polymorphism however
does not make a distinction between BCG and non-BCG
M. bovis. Based on patient clinical history and the fact
that zoonotic M. bovis infections would be almost non-
existent in a non-cattle farming setting such as ours [18],
M. bovis BCG would be the presumptive identification.
Distinguishing BCG from M. bovis is not a simple task.
Phenotypically both species are susceptible to thiophene-2-
carboxylic acid hydrazide and resistant to pyrazinamide
although M. bovis has a preference for microaerophilic
conditions compared to BCG which displays aerophilic
growth (13). HPLC analysis of mycolic acid esters can be
used for confirmation of BCG strains as it possesses a pro-
file that is unique from M. bovis however it is a method
that is restricted to being carried out at a mycobacterial
reference laboratory (9). Comparatively, molecular testing
offers accessibility and rapidity. Apart from the exploitation
of RD profiles for species differentiation, the size-variable
senX3-regX3 intergenic region has also been targeted [19].
PCR assays that utilize the senX3-regX3 intergenic region
are also typically used in conjunction with the RD targets
thereby underscoring the importance of RD for differenti-
ating TBC members [20].
Other tests routinely performed in our laboratory for
the identification of members of the TBC include the
AccuProbe Mycobacterium tuberculosis complex test and
the SD TB Ag MPT64 Rapid test. The AccuProbe Myco-
bacterium tuberculosis complex test is used for the identi-
fication of TBC members and as anticipated it did not
differentiate between BCG and TB. All the BCG cases as
well as the clinical TB cases tested positive with this kit
(Table 1). The SD TB Ag MPT64 Rapid is an immuno-
chromatographic test detecting MPT64, an antigen se-
creted by members of the TBC. Most BCG vaccine strains
do not secrete MPT64 nevertheless exceptions have been
noted [21,22]. Strains like BCG Tokyo and BCG Russia
still retain the gene for MPT64 and the capacity to secrete
the antigen [21,23]. These vaccines strains could still test
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MTB isolates gave positive results with the SD TB Ag
MPT64 Rapid test. In contrast, all the BCG suspected
cases tested negative (Table 1). In Singapore, since June
2003, BCG Danish strain 1331 has been the sole vaccine
type [24]. This strain lacks MPT64 [23] and will therefore
be negative on the SD TB Ag MPT64 Rapid test.
Prior to establishment of the PCR assay, specimens for
BCG confirmation were sent to a reference laboratory for
HPLC analysis. Here, we present evaluation data demon-
strating the clinical validity of the RD1, RD9 and hsp65
based PCR assay for the rapid detection and differenti-
ation of M. bovis BCG. Its reliability and ease of use has
made it feasible for incorporation as a routine mycobac-
terial diagnostic service in our laboratory.
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